EXECUTION VERSION

Confidential

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

FIRST AMENDMENT TO
LICENSE AGREEMENT

THIS FIRST AMENDMENT TO THE LICENSE AGREEMENT(“Amendment”) is entered into and effective as of April 23, 2024 (the “Amendment Date”), by and between MELINTA THERAPEUTICS, LLC, a Delaware limited liability company, having a place of business at 389 Interpace Parkway, Suite 450, Parsippany, NJ 07054 (together with its subsidiaries, “Melinta”), and CIDARA THERAPEUTICS, INC., a corporation organized under the laws of the State of Delaware, USA, having its principal offices at 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121, USA (“Cidara”).

RECITALS

WHEREAS, Melinta and Cidara are parties to that certain License Agreement dated July 26, 2022 (the “Agreement”);

WHEREAS, Melinta and Cidara desire to make certain modifications to the terms and conditions of the Agreement; and

WHEREAS, the parties now wish to amend the Agreement as expressly set forth herein.

AGREEMENT

Now, THEREFORE,in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1.Defined Terms. Capitalized terms used but not otherwise defined in this Amendment shall have the meanings provided in the Agreement.

…

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Confidential

LICENSE AGREEMENT

THIS LICENSE AGREEMENT (this “Agreement”) dated as of July 26, 2022 (the “Effective Date”), is entered into between Cidara Therapeutics, Inc., a Delaware corporation (“Cidara”), having a place of business at 6310 Nancy Ridge Drive, Suite 101, San Diego, CA 92121, and Melinta Therapeutics, LLC, a Delaware limited liability company (together with its subsidiaries, “Melinta”), having a place of business at 44 Whippany Road, Suite 280, Morristown, NJ 07960.

WHEREAS, Cidara owns or has rightsin the Compound (as defined below).

WHEREAS, Melinta desires to obtainan exclusive license under Cidara’s rights to the Compound in the Territory (as defined below) on the terms and conditions set forth below.

NOW, THEREFORE, in considerationof the foregoing premises and the mutual covenants herein contained, the parties hereby agree as follows:

1.DEFINITIONS

For purposes of this Agreement, the terms defined in this Section 1 shall have the respective meanings set forth below:

…

Exhibit 10.1

Execution Version

** **

VEEA INC.

Common Stock

($0.0001 par value per share)

** **

Sales Agreement

August 13, 2026

Roth Capital Partners, LLC

888 San Clemente Drive, Suite 400

Newport Beach, CA 92660

Ladies and Gentlemen:

Veea Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (the “Agent”), as follows:

1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through or to the Agent, shares (the “Placement Shares”) of common stock of the Company, $0.0001 par value per share (the “Common Stock”), provided, however, that in no event shall the Company issue or sell through Agent such number of Placement Shares that (a) exceeds the number or dollar amount of shares of Common Stock that may be sold pursuant to the Registration Statement (as defined below), or (b) exceeds the number of authorized but unissued shares of Common Stock of the Company (the “Maximum Amount”). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth in this Section 1 on the amount of Placement Shares issued and sold under this Agreement shall be the sole responsibility of the Company and that Agent shall have no obligation in connection with such compliance. The issuance and sale of Placement Shares through or to Agent will be effected pursuant to the Registration

…

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”.

CREDIT AGREEMENT

BETWEEN

ENOVUM DATA CENTERS CORP.

as Borrower

** **

AND

** **

ENOVUM MTL I GP INC., EDC MTL I LIMITED PARTNERSHIP, ENOVUM MTL II GP INC., EDC MTL II LIMITED PARTNERSHIP, ENOVUM SAINT-JEROME GP INC., EDC SAINT-JÉRÔME LIMITED PARTNERSHIP and 1504950 B.C. UNLIMITED LIABILITY COMPANY

as Guarantors

** **

AND

THE FINANCIAL INSTITUTIONS from time to time party to this Agreement and designated
as Lenders on the signature pages hereto

as Lenders

** **

AND

** **

ROYAL BANK OF CANADA

as Administrative Agent

** **

AND

** **

ROYAL BANK OF CANADA

as Sole Lead Arranger and Sole Bookrunner

---

MADE AS OF

** **

JULY 6, 2026

** **

---

** **

TABLE OF CONTENTS

…

KARYOPHARM THERAPEUTICS INC.

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

The purpose of this Non-Employee Director Compensation Policy (this “Policy”) of Karyopharm Therapeutics Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors and reflect the substantial time commitment necessary to oversee the Company’s affairs. In furtherance of this purpose, non-employee members of the board of directors (the “Board”) of the Company shall be eligible to receive cash and equity compensation as set forth in this Policy. The cash compensation and equity grants described in this Policy shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a “Non-Employee Director”), unless such Non-Employee Director declines the receipt of such cash compensation or equity grants by written notice to the Company. This Policy shall be reviewed by the Compensation Committee of the Board periodically and may be amended, modified or terminated by the Board at any time in its sole discretion. The terms and conditions of this Policy shall supersede any prior cash and/or equity compensation program with respect to service as a member of the Board. This Policy shall become effective on the date set forth below, with any amendments to the Policy becoming effective on the date set forth below (such date, the “Effective Date”).

1.

Cash Compensation

…

KARYOPHARM THERAPEUTICS INC.

Restricted Stock Unit Agreement

(Non-Employee Director)

2022 Equity Incentive Plan

NOTICE OF GRANT

This Restricted Stock Unit Agreement (this “Agreement”) is made as of the Agreement Date between Karyopharm Therapeutics Inc. (the “Company”), a Delaware corporation, and the Participant. Agreement Date and Number

Agreement Date:
Agreement Number:

(a)

Participant Information

Participant:
Participant Address:

(b)

Grant Information

Grant Date:
Number of Restricted Stock Units:

(c)

Vesting Table

Vesting Date:	One year anniversary of the Grant Date

This Agreement includes this Notice of Grant and the following Exhibit, which is expressly incorporated by reference in its entirety herein.

Exhibit A – General Terms and Conditions

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Agreement Date.

By:________________________

Name of Officer: Lori Macomber
Title: Chief Financial Officer
Karyopharm Therapeutics Inc.

…

KARYOPHARM THERAPEUTICS INC.

Restricted Stock Unit Agreement (Performance Vested)

2022 Equity Incentive Plan

NOTICE OF GRANT

This Restricted Stock Unit Agreement (this “Agreement”) is made as of the Agreement Date between Karyopharm Therapeutics Inc. (the “Company”), a Delaware corporation, and the Participant.

Agreement Date:
Agreement Number:

I.

Participant Information

Participant:
Participant Address:

II.

Grant Information

Grant Date:
Restricted Stock Units:

III.

Vesting Table

…

KARYOPHARM THERAPEUTICS INC.

Restricted Stock Unit Agreement (Performance Vested)

2022 Equity Incentive Plan

NOTICE OF GRANT

This Restricted Stock Unit Agreement (this “Agreement”) is made as of the Agreement Date between Karyopharm Therapeutics Inc. (the “Company”), a Delaware corporation, and the Participant.

Agreement Date:
Agreement Number:

I.

Participant Information

Participant:
Participant Address:

II.

Grant Information

Grant Date:
Restricted Stock Units:

III.

Vesting Table

…

AMENDMENT NO. 5 TO

2022 EQUITY INCENTIVE PLAN OF

KARYOPHARM THERAPEUTICS INC.

In accordance with Section 12(d) of the 2022 Equity Incentive Plan (the “Plan”) of Karyopharm Therapeutics Inc. (the “Company”), the Plan is hereby amended, effective as of the date of approval by the Board of Directors of the Company, as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan):

1. Section 4(a)(1)(A) of the Plan be and hereby is deleted in its entirety and the following is inserted in lieu thereof:

5,406,666 shares of Common Stock; and

2. Except as expressly amended herein, the Plan and all of the provisions contained therein shall remain in full force and effect.

* * *

Approved by the Board of Directors on May 22, 2026

Approved by the Stockholders on ______ __, 202__*

*If stockholder approval is not obtained on or prior to May 31, 2027, then the shares subject to this Amendment shall terminate and shall cease to be available under the Plan; provided, however, that if stockholders approve a lesser number of shares on or prior to May 31, 2027, then the amount listed above shall be reduced to reflect the approval of such lesser number of shares.

---

SPRINKLR, INC.

AMENDED AND RESTATED

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Sprinklr, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) for his or her service on the Board.

An Eligible Director may decline all or a portion of their compensation by giving notice to the Company prior to the date on which quarterly cash payments are to be paid, or equity awards are to be granted, subject to compliance with applicable tax laws. This policy is effective as of May 27, 2026 (the “Effective Date”) and may be amended at any time by the Board or the Compensation Committee of the Board (the “Compensation Committee”).

Annual Cash Compensation

…

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

AMENDMENTTOSERVICEAGREEMENT,July1,2026-November15,2027

CICandClientherebyagreetosupplementtheServiceAgreementasfollows:

Section1.License

NotwithstandingthefinalsentenceofSection1,thepartiesagreethatClientwillhavealicensetouseandoccupy the Space as provided in Section 2 below from July 1, 2026 - November 15, 2027 [the Term].

ThisSpace-SpecificAmendmentreplacestheamendmentsexecutedbyClientprevioustothesigningofthis document, which the parties agree is now null and void.

As this is a fixed term agreement, you will be responsible for payment of your fees for your term, even if you choosetovacateyourspacebeforetheendofyourterm.Exceptionstothismayonlybemadebymutualagreement in writing signed by both parties.

If Client occupies any other part of any CIC Premises beyond the Space listed in Section 2 during the Term or the 12monthextensionterms,suchoccupancywillnotbesubjecttotheamendedterminationrightsassetforthherein.

Section2.SpaceandServices

ThebelowSpacesareincludedinthisTerm:

…

Exhibit 10.2

THIRDAMENDMENTTOLEASE

THISTHIRDAMENDMENTTOLEASE(“Amendment”)ismadeandenteredintoasof April 14, 2026,byandbetweenBRANDYWINECIRA,L.P.,aPennsylvanialimitedpartnership ("Landlord"),andCABALETTABIO,INC.,aDelawarecorporation("Tenant”).

A.

Landlordand Tenantare parties to a Lease ("OriginalLease")dated as of February11, 2019, as amendedbya First Amendmentto Lease dated asof February 15, 2022, and a Second Amendment to Lease dated asof October 1,2024 (the OriginalLease assoamended is referred to herein asthe"CurrentLease"),for the Premises deemed tocontain 7,672 rentable square feet presently known as Suite 600 in the Building known asCira Centre located at 2929 Arch Street,Philadelphia, Pennsylvania.TheCurrentLease as amendedby this Amendmentis referredto hereinas the "Lease".

B.

The Term currently expires on June 30, 2026. Landlord and Tenant agree to amend the CurrentLease to extendthe Termupon the terms and conditions set forth herein.

NOW, THEREFORE, inconsideration ofthemutual covenants andagreementscontained herein, and intending tobelegallybound, LandlordandTenant hereby agreeasfollows:

1.

Incorporation of Recitals: Definitions.The recitals set forth above are hereby incorporated herein by reference as if set forth in full in the body of this Amendment. Capitalized terms used but not otherwise definedin thisAmendmenthave the respective meaningsgivento them in the CurrentLease.

2.

Term.TheTermisherebyextendedthroughNovember15,2027.

3.

…